Teleflex Q2 2026: Revenue +28.9% on VI acquisition, net income -18.7%, OEM sold for $570.3M

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 31, 2025 · ~1 min read

Key Changes

• high

  Net income fell 18.7% to $99.7M and diluted EPS fell 17.7% to $2.28 despite 28.9% revenue growth, as operating income declined 20% to $570.3M on gross margin compression (down 190bp in Q2, 370bp for six months) from tariffs, VI Business's lower margin profile, and integration costs.

  MD&A: Operating Results verify on EDGAR →
• high

  OEM business sold August 3, 2026 for $1.5B net proceeds (~$1.2B after-tax), generating an estimated $1.0B pre-tax gain; proceeds used to pay off $700M term A-2 loan. Acute Care and Interventional Urology businesses remain held for sale.

  Notes: Strategic Divestitures verify on EDGAR →
• high

  Company repurchased 1.9M shares for $250M in Q2 2026 under a $1B authorization approved December 2025, leaving $750M remaining.

  MD&A: Share Repurchase verify on EDGAR →